Recent clinical trials have shown that finerenone, a selective nonsteroidal MR antagonist (the third and newest generation), reduces risks of chronic kidney disease progression and cardiovascular events in patients with chronic kidney disease and type 2 diabetes (49, 50), with the expectation to have broader cardiovascular indications (51). Here, NR3C2 is linked to type 2 diabetes mellitus.